300357.SZ SHZ
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
1W: +0.7%
1M: -9.1%
3M: -14.9%
YTD: -26.9%
1Y: -22.1%
3Y: -40.1%
5Y: -65.3%
¥20.33 ($3.03)
+0.51 (+2.57%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$2.7B
+5.7% ▲
5Y CAGR: +13.7%
Total Liabilities
$250M
-3.2% ▼
5Y CAGR: +26.8%
Shareholders Equity
$2.4B
+7.7% ▲
5Y CAGR: +13.1%
Cash & Investments
$1.3B
+2.0% ▲
5Y CAGR: +10.7%
Total Debt
$21M
-63.1% ▼
Net Debt
-$1.1B
+1.0% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $584M | $650M | $841M | $1.2B | $1.1B |
| Short-Term Investments | $307M | $371M | $295M | $117M | $196M |
| Cash & ST Investments | $891M | $1.0B | $1.1B | $1.3B | $1.3B |
| Net Receivables | $227M | $249M | $274M | $203M | $258M |
| Inventory | $48M | $54M | $48M | $59M | $58M |
| Other Current Assets | $4K | $29M | $39M | $19M | $18M |
| Total Current Assets | $1.2B | $1.3B | $1.5B | $1.6B | $1.7B |
| Property, Plant & Equip. | $240M | $302M | $445M | $705M | $780M |
| Goodwill & Intangibles | $170M | $176M | $189M | $188M | $182M |
| Long-Term Investments | -$293M | -$288M | -$217M | -$43M | -$118M |
| Other Non-Current Assets | $312M | $394M | $298M | $137M | $209M |
| Total Non-Current Assets | $434M | $590M | $721M | $992M | $1.1B |
| Total Assets | $1.6B | $1.9B | $2.2B | $2.6B | $2.7B |
| — Liabilities — | |||||
| Accounts Payable | $6M | $5M | $8M | $8M | $48M |
| Short-Term Debt | $0 | $0 | $0 | $34M | $13M |
| Deferred Revenue | $441K | $417K | $0 | $384K | $0 |
| Other Current Liabilities | $54M | $102M | $95M | $7M | $6M |
| Total Current Liabilities | $55M | $108M | $103M | $177M | $183M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $0 | $0 | $56M | $60M | $26M |
| Total Non-Current Liabilities | $21M | $27M | $68M | $81M | $68M |
| Total Liabilities | $77M | $135M | $171M | $258M | $250M |
| — Equity — | |||||
| Common Stock | $524M | $524M | $524M | $524M | $524M |
| Retained Earnings | $647M | $890M | $1.1B | $1.3B | $1.4B |
| Accumulated OCI | $157M | $195M | $235M | $271M | $271M |
| Total Stockholders Equity | $1.5B | $1.7B | $2.0B | $2.2B | $2.4B |
| Total Liabilities & Equity | $1.6B | $1.9B | $2.2B | $2.6B | $2.7B |
| — Key Metrics — | |||||
| Total Debt | $10M | $8M | $16M | $56M | $21M |
| Net Debt | -$574M | -$642M | -$824M | -$1.1B | -$1.1B |
| Total Investments | $14M | $83M | $78M | $74M | $78M |